Teva taps new CFO, hikes legal set-aside to more than $1B as opioid deal falters

Teva
Teva has expanded its legal set-aside to more than $1 billion as a massive opioid deal hangs in the balance. (Teva)

Aiming to settle the thousands of opioid lawsuits it faces, Teva has proposed an eye-popping $23 billion-plus deal with plaintiffs. So far, that offer hasn't gained much traction, though, leaving the drugmaker with a legal overhang that just tops 10 figures. 

Teva set aside another $468 million to cover its legal costs as it works to negotiate that settlement, bringing its total this year to more than $1.1 billion. 

Teva's outgoing CFO Mike McClellan––set to be replaced next month by Flex's Eli Kalif––said Thursday that the amount represents the low end of Teva's potential liabilities and could grow if a settlement is reached. "Our expectation is to eventually––once there’s a settlement––there will be much more clear number," McClellan said during the company's Q3 earnings call. "Nothing is more probable than what we’ve reserved."

RELATED: J&J, Teva offer a whopping $48B combined to wrap opioid suits, but not all plaintiffs are on board

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.